By Stephen Nakrosis 
 

Vir Biotechnology Inc. and GlaxoSmithKline PLC on Thursday said the first patient had been dosed in a trial to evaluate VIR-7831 to treat hospitalized adults with Covid-19.

The companies said the "randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with Covid-19."

The trial is being carried out under the auspices of the National Institutes of Health's Accelerating Covid-19 Therapeutic Interventions and Vaccines, or ACTIV, Program Phase 3, the companies said. "ACTIV-3 is one of several ongoing trials in the NIH's ACTIV program, an NIH-led public-private partnership designed to accelerate development of the most promising treatments and vaccine candidates for Covid-19," the companies said.

George Scangos, the chief executive officer of Vir, said, "Recent data suggest that the neutralizing activity of antibodies may be insufficient to protect hospitalized adults from the most severe consequences of Covid-19. We are hopeful that the differentiating factors and broad anti-coronavirus activity of VIR-7831 may allow it to help those patients and add to our preparedness for related coronaviruses that could emerge in the future."

In addition to the Phase 3 ACTIV-3 trial, VIR-7831 is being evaluated in the global Phase 2/3 COMET-ICE trial for the early treatment of Covid-19 in adults at high risk of hospitalization, the companies said.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

December 17, 2020 18:15 ET (23:15 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 2 2024 まで 3 2024 Gskのチャートをもっと見るにはこちらをクリック
Gsk (LSE:GSK)
過去 株価チャート
から 3 2023 まで 3 2024 Gskのチャートをもっと見るにはこちらをクリック